Roundup: eMedAsia offers an overview of the COVID-19 website, Phablecare’s purchase of Fused Training, and more briefings.

Hong Seng’s eMedAsia, CLEA partner to provide virtual COVID-19 coverage for global travel

Malaysian digital health platform eMedAsia has started offering COVID-19 testing services through its partnership with CLEA Technology.

His partner provides COVID-19 RTK and PCR virtual screening services through the CLEADOC software. It provides travelers seeking COVID-19 tests as a requirement prior to departure or arrival. CLEADOC has physicians on board to verify in-app reporting results.

EMedAsia, a joint venture between Hong Seng Consolidated and KOOP MMA, the founding arm of the Malaysian Medical Association, is offering a web -based testing service to inbound and outbound athletes to prepare for the next level of training. the reopening of the Malaysian border.

“Malaysia is expected to host more than four million visitors and most Malaysians are expected to travel abroad after the borders reopen,” said Director Dr Thirunavukarasu Rajoo.

Today, eMedAsia teamed up with government MySafeTravel to expand its network of 2,000 private clinics with travelers.


Phablecare buys Indian health technology startup Fused Training diabetes management platform

Phablecare has received the launch of Fused Training, a physical activity site dedicated to type 1 diabetes patients, for an undisclosed amount.

Founded in 2018, Phablecare provides patient care through its mobile app, currently serving over three million patients and over 10,000 doctors across India.

Combining scientific knowledge and practical knowledge, Fused Training creates programs designed for patients with type 1 diabetes.

Its acquisition, according to a press release, adds type 1 diabetes management to the Phablecare portfolio and allows its users to participate in Fused Training programs.

“While it is the only company working on the treatment of type 1 diabetes and physical activity in India, we are excited to begin this new journey with the Phablecare group… Projects in this transformation. , ”said Fused Training founder Sahil Madan.


Terumo combines the insulin tablet with the Glooko tablet

Japanese pharmaceutical manufacturer Terumo and Glooko, a provider of remote -control medical technology for diabetes, have teamed up.

According to a press release, they have been able to combine users of Terumo’s MEDISAFE WITH insulin patch pump to upload their stored data into the Glooko site, where their insulin will be displayed. dosage, diet, and activities in the form of diagrams.

Patients can share their data with their doctors, and then they can view their patients’ medical records through the Glooko window.

“This is the way people with the disease can make informed decisions with their data, and collaborate with their health care team,” Glooko CEO Russ Johannesson said of their integration offer, available in Europe from May.

Terumo and Glooko are also working on another model to upload diabetes data to the Glooko platform via near field chat, which is coming to Europe later this year.

“These new solutions will allow people with diabetes to upload their data from home without the hassle of visiting the hospital. We believe this is a significant impact for patients and caregivers. health, much below the post-COVID-19 ‘new normal’ life, ”said Hikaru Samejima, president of Terumo’s General Hospital Company.

Related Posts

Leave a Reply

Your email address will not be published.